Clinical trial simulations of the interaction between cannabidiol and clobazam and effect on drop‐seizure frequency-Reference-Cited by-同舟云学术

Clinical trial simulations of the interaction between cannabidiol and clobazam and effect on drop‐seizure frequency

Published:2019-12-12 Issue:2 Volume:86 Page:380-385
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Bergmann Kirsten Riber¹,Broekhuizen Karen¹^ORCID,Groeneveld Geert Jan¹

Affiliation:

1. Centre for Human Drug Research Leiden The Netherlands

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.14158

Reference28 articles.

1. Nonpsychotropic Plant Cannabinoids, Cannabidivarin (CBDV) and Cannabidiol (CBD), Activate and Desensitize Transient Receptor Potential Vanilloid 1 (TRPV1) Channels in Vitro: Potential for the Treatment of Neuronal Hyperexcitability

2. Molecular Targets of Cannabidiol in Neurological Disorders

3. Validation of corneally kindled mice: a sensitive screening model for partial epilepsy in man

4. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1and CB2

5. Pharmaceuticals G.GW Pharmaceuticals announces the European Medicines Agency (EMA) accepts Epidiolex (R) (cannabidiol) marketing authorization application (MAA) for review2018. Available from:https://www.gwpharm.com/about/news/gw‐pharmaceuticals‐announces‐european‐medicines‐agency‐ema‐accepts‐epidiolexr.

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Does the “Entourage Effect” in Cannabinoids Exist? A Narrative Scoping Review;Cannabis and Cannabinoid Research;2023-08-03

2. Proposed anti-seizure medication combinations with rufinamide in the treatment of Lennox-Gastaut syndrome: Narrative review and expert opinion;Seizure: European Journal of Epilepsy;2023-08

3. Real-world, long-term evaluation of the tolerability and therapy retention of Epidiolex® (cannabidiol) in patients with refractory epilepsy;Epilepsy & Behavior;2023-04

4. A scoping review on cannabidiol therapy in tuberous sclerosis: Current evidence and perspectives for future development;Epilepsy & Behavior;2022-03

5. Over the counter low-dose cannabidiol: A viewpoint from the ACRE Capacity Building Group;Journal of Psychopharmacology;2021-08-03